(NYSE: TEVA) Teva Pharmaceutical Industries's forecast annual revenue growth rate of 1.66% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Teva Pharmaceutical Industries's revenue in 2024 is $16,004,000,000.On average, 4 Wall Street analysts forecast TEVA's revenue for 2024 to be $18,046,017,176,619, with the lowest TEVA revenue forecast at $17,978,460,828,211, and the highest TEVA revenue forecast at $18,231,436,105,551. On average, 4 Wall Street analysts forecast TEVA's revenue for 2025 to be $18,726,552,952,920, with the lowest TEVA revenue forecast at $18,383,776,265,847, and the highest TEVA revenue forecast at $19,269,920,289,722.
In 2026, TEVA is forecast to generate $18,969,874,734,452 in revenue, with the lowest revenue forecast at $18,524,790,020,174 and the highest revenue forecast at $19,585,621,203,324.